Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies.
Because of the need for control of beta-lactamase-mediated resistance and the recent development of tazobactam, the author has examined the inhibitors of various beta-lactamases for their effectiveness. On the basis of the kinetic data, tazobactam exhibited the highest affinity to various beta-lactamases. A combination with tazobactam was found to enhance the effectiveness of piperacillin against S. aureus producing penicillinase, E. coli producing TEM-1 or TEM 2 enzymes and class I beta-lactamase-derepressed isolates of E. cloacae, Serratia spp. and C. freundii, however not P. aeruginosa, while there was no marked synergism in beta-lactamase-derepressed clones of K. oxytoca.
Cullmann
W
W
Dept. Med. Microbiology and Immunology, Ruhr-Universität, Bochum.
D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000494:pharmacology; D004338:Drug Combinations; D004357:Drug Synergism; D016972:Enterobacter cloacae / Q000187:drug effects / Q000201:enzymology; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D007709:Klebsiella / Q000187:drug effects / Q000201:enzymology; D010397:Penicillanic Acid / Q000494:pharmacology*; D010878:Piperacillin / Q000494:pharmacology*; D011514:Proteus vulgaris / Q000187:drug effects / Q000201:enzymology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000201:enzymology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000201:enzymology; D013407:Sulbactam / Q000494:pharmacology; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
D002969:Clavulanic Acids; D004338:Drug Combinations; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D010397:Penicillanic Acid; D013407:Sulbactam; D000078142:Tazobactam; D010878:Piperacillin